Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


FDA approves Zoryve (roflumilast) cream 0.15% for the treatment of atopic dermatitis in adults and children down to 6 years of age – Arcutis Biotherapeutics

Written by | 13 Jul 2024

Arcutis Biotherapeutics, Inc. announced the FDA has approved the supplemental new drug application (sNDA) for Zoryve (roflumilast) cream, 0.15%, for the treatment of mild to moderate atopic dermatitis… read more.

ASCO: Neoadjuvant therapy shows superiority for resectable stage III melanoma

Written by | 27 Jun 2024

ASCO: In resectable stage III melanoma, treatment with the immunotherapies ipilimumab and nivolumab before lymph nodes are surgically removed is more effective than treatment with nivolumab after the… read more.

FDA approves Klisyri (tirbanibulin) for the treatment of actinic keratosis on expanded area of face or scalp up to 100 cm – Almirall

Written by | 21 Jun 2024

Almirall, announced that the FDA has approved Almirall’s recent supplemental New Drug Application (sNDA) to expand the use area for its drug, Klisyri, to up to 100 cm…. read more.

Drug used to treat eczema may provide relief for patients with intensely itchy skin diseases

Written by | 16 Jun 2024

A drug approved to treat eczema provided significant improvement in the symptoms of patients with severe itching diseases that currently have no targeted treatments, according to a new… read more.

New project to tackle tanning perceptions in young people, offering crucial boost to sun-safety education in Wales

Written by | 15 Jun 2024

A Swansea University-led project hopes to help stop the concerning rise of skin cancer in Wales by exploring current perceptions of tanning in children, parents/carers, and educators. The… read more.

Why do 1 in 10 Americans get eczema? Is it too much salt?

Written by | 6 Jun 2024

UCSF Study finds that changes in daily salt intake may explain eczema flares. A high sodium diet may increase the risk of eczema, according to researchers at UC… read more.

New four-Year Sotyktu (deucravacitinib) data demonstrates durable response rates and consistent safety in moderate-to-severe plaque psoriasis – BMS

Written by | 22 May 2024

Bristol Myers Squibb announced new four-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) treatment in adult patients with moderate-to-severe plaque psoriasis. After four… read more.

Survey finds young adults more likely to believe myths about sun protection and skin cancer prevention

Written by | 3 May 2024

A new national survey by the Orlando Health Cancer Institute finds nearly a third (32%) of Americans agree that a tan makes people look better and healthier, a dangerous beauty… read more.

New data show Rinvoq (upadacitinib) demonstrated superiority versus Dupixent (dupilumab) across primary and all secondary endpoints in an open-label head-to-head atopic dermatitis study – Abbvie

Written by | 3 May 2024

AbbVie announced positive topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase IIIb/IV study that evaluated the efficacy and safety of upadacitinib (Rinvoq, 15 mg once… read more.

The dermatology initiative that could reduce NHS wait lists

Written by | 28 Mar 2024

Giving GPs cameras to photograph skin complaints could help slash wait times for hospital appointments according to a new service evaluation from the University of East Anglia. An… read more.

New research reveals genomic profile of seborrheic dermatitis and answers key questions on immune response and skin barrier dysfunction – Arcutis Biotherapeutics Inc

Written by | 12 Mar 2024

Arcutis Biotherapeutics, Inc., highlights new research that, for the first time, reveals the gene expression profile of seborrheic dermatitis . The Arcutis sponsored research from The Kimberly and… read more.

Arcutis and Sato announce strategic collaboration and licensing agreement for topical roflumilast in Japan

Written by | 4 Mar 2024

Arcutis Biotherapeutics, Inc. and Sato Pharmaceutical Co., Ltd., a leading pharmaceutical company, announced that the companies have entered into a strategic collaboration and licensing agreement for the development,… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.